Novavax's Earnings Estimates: What to Know

Novavax (NVAX) has seen a 14% return in the past month, outperforming the Zacks S&P 500 composite's 2.7% change. The vaccine maker is expected to post a loss of $0.26 per share for the current quarter, a year-over-year change of +65.8%. The consensus earnings estimate for the current fiscal year is $2.68, indicating a year-over-year change of +317.9%. The Zacks Rank is #3 (Hold) due to the recent change in the consensus estimate.

Novavax (NVAX), a vaccine maker, ended the recent trading session at $8.68, registering a -2.2% change from the previous day's close. This decline lagged the S&P 500's 0.55% loss on the day, while the Dow and tech-heavy Nasdaq lost 0.19% and 0.95%, respectively. Over the past month, shares of Novavax gained 17.95%, outperforming the Zacks S&P 500 composite's 2.7% change Novavax (NVAX) Declines More Than Market: Some Information for Investors^[1].

Analysts anticipate that Novavax will report a loss of -$0.26 per share for the current quarter, representing year-over-year growth of 65.79%. For the full year, the Zacks Consensus Estimates project earnings of $2.68 per share, indicating a year-over-year change of +317.89%. Revenue is expected to reach $1.03 billion, up 51.52% from the prior year Novavax (NVAX) Declines More Than Market: Some Information for Investors^[1].

The Medical sector, which includes Novavax, lost 0.2% in the past month, while the S&P 500 gained 3.64%. The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 102, placing it in the top 42% of all industries. The industry's average PEG ratio is 1.67, compared to Novavax's current PEG ratio of 0.12, indicating a discount relative to industry peers Novavax (NVAX) Declines More Than Market: Some Information for Investors^[1].

Novavax's Zacks Rank is currently #3 (Hold), reflecting the recent upward shift in the consensus EPS estimate by 0.75%. The company's Forward P/E ratio of 3.31 is lower than the industry average of 19.47, suggesting undervaluation. Investors should monitor Novavax's upcoming financial results and any changes in analyst estimates to gauge the company's near-term performance Novavax (NVAX) Declines More Than Market: Some Information for Investors^[1].